openPR Logo
Press release

Biosimilar Market size was valued at CAGR of 17.02 % in the Forecast Period of 2024 to 2030

Biosimilar Market

Biosimilar Market

The Biosimilar Market size was valued at USD 24.86 Billion in 2023 and the total Biosimilars revenue is expected to grow at a CAGR of 17.02 % from 2024 to 2030, reaching nearly USD 74.70 Billion by 2030.

Biosimilar Market Overview:

The global biosimilar market is experiencing significant growth, driven by the expiration of patents for major biologic drugs, escalating healthcare costs, and the increasing demand for affordable treatment options. Biosimilars, which are highly similar and functionally identical versions of approved reference biologics, offer cost-effective alternatives without compromising efficacy or safety. Key industry players, including Pfizer, Sandoz (Novartis), Amgen, and Biocon, have made substantial advancements in this field. For instance, Pfizer's biosimilar portfolio features Ruxience (rituximab), approved for multiple indications, thereby expanding patient access to essential therapies. Amgen's Kanjinti (trastuzumab) addresses critical needs in breast cancer treatment. Strategic collaborations, such as the partnership between Biocon and Mylan, have further propelled biosimilar developments, aiming to meet unmet medical needs and broaden market reach.​

Download a Free Sample Report Today : https://www.maximizemarketresearch.com/request-sample/83592/

Biosimilar Market Dynamics

The expiration of patents for biological drugs serves as a pivotal driver for the biosimilar market, creating opportunities for new entrants and fostering competition. For example, the patent expiry of Humira has led to the introduction of biosimilars like Amgen's Amjevita and Pfizer's Abrilada, offering cost-effective alternatives for autoimmune conditions. This increased competition results in reduced treatment costs, benefiting both patients and healthcare systems. Additionally, the rising incidence of chronic diseases has heightened the demand for affordable treatment options, further fueling the growth of biosimilars. Supportive regulatory frameworks, particularly in regions like Europe, have facilitated the approval and adoption of biosimilars, ensuring their quality and efficacy.​

Biosimilar Market Outlook and Future Trends :

The biosimilar market is poised for continued expansion, with projections indicating a compound annual growth rate (CAGR) of 17.02% from 2024 to 2030, reaching nearly USD 74.70 billion by 2030. Future trends include the development of biosimilars for a broader range of therapeutic areas, increased investments in research and development, and the formation of strategic alliances to enhance market penetration. The emphasis on cost containment in healthcare spending and the need for accessible treatments are expected to further drive the adoption of biosimilars globally.​

Key Recent Developments

Vietnam

In September 2024, Celltrion completed the establishment of its overseas corporation in Vietnam, marking a significant step in expanding its presence in the Southeast Asian biosimilar market. ​

Thailand

As of now, specific merger and acquisition activities in the biosimilar sector within Thailand have not been prominently reported.​

Japan

In November 2023, Ajinomoto acquired US-based Forge Biologics for $620 million, aiming to bolster its capabilities in the biologics sector and expand its global footprint. ​

South Korea

In November 2024, Celltrion acquired iQone Healthcare Switzerland for approximately 30 billion won ($21 million), enhancing its distribution channels and market access in Europe. ​

Singapore

In May 2023, Ajinomoto signed a letter of intent for a strategic alliance with Solar Foods, a company that developed Solein, a microbial protein feeding on CO2 as a nutrient source, and obtained a marketing license in Singapore.

United States

In November 2022, Viatris completed the sale of its biosimilars portfolio to Biocon Biologics for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics. ​

Europe

In November 2024, Celltrion acquired iQone Healthcare Switzerland, a pharmaceutical company, for around 30 billion won ($21 million), aiming to strengthen its European market presence. ​

Biosimilar Market Segmentation

by Type

Human growth hormone
Erythropoietin
Monoclonal antibodies
Insulin
Granulocyte-colony stimulating factor
Others

by Technology

Recombinant DNA Technology
Monoclonal Antibodies (MAb) Technology

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report : https://www.maximizemarketresearch.com/market-report/global-biosimilar-and-follow-on-biologics-market/83592/

Some of the current players in the Biosimilar Market are:

North America:
1. Pfizer Inc.
2. Amgen Inc.
3. Coherus BioSciences
4. Viatris (formerly Mylan)
5. Teva Pharmaceutical Industries
Europe:
1. Novartis AG (Sandoz)
2. Biocon Biologics
3. Samsung Bioepis
4. Fresenius Kabi
5. Biogen
Asia-Pacific:
1. Biocon Biologics
2. Samsung Bioepis
3. Celltrion Inc.
4. Dr. Reddy's Laboratories
5. Lupin Limited

Conclusion

The global biosimilar market is undergoing transformative growth, driven by patent expirations, the need for cost-effective therapies, and supportive regulatory environments. Strategic mergers and acquisitions across various countries are further shaping the competitive landscape, enhancing the accessibility and affordability of biologic treatments worldwide.

For additional reports on related topics, visit our website:

♦ Global Gastrointestinal Therapeutics Market https://www.maximizemarketresearch.com/market-report/global-gastrointestinal-therapeutics-market/38877/

♦ global Medical Tourism Market https://www.maximizemarketresearch.com/market-report/global-medical-tourism-market/34172/

♦ Bio-implant Market https://www.maximizemarketresearch.com/market-report/global-bio-implants-market/110876/

Contact Maximize Market Research:

MAXIMIZE MARKET RESEARCH PVT. LTD.
⮝ 3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
✆ +91 9607365656
🖂 sales@maximizemarketresearch.com

About Maximize Market Research:

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Market size was valued at CAGR of 17.02 % in the Forecast Period of 2024 to 2030 here

News-ID: 3954082 • Views:

More Releases from MAXIMIZE MARKET RESEARCH PVT. LTD.

Clinical Trials Market Set to Reach USD 88.26 Billion by 2032 with a 6.13% CAGR - Clinical Trials Market Forecast Insights
Clinical Trials Market Set to Reach USD 88.26 Billion by 2032 with a 6.13% CAGR …
According to a new report by Maximize Market Research, the global Clinical Trials Market was valued at USD 54.83 billion in 2024 and is projected to reach USD 88.26 billion by 2032, growing at a CAGR of 6.13%. A major surge in biopharmaceutical R&D and oncology-focused studies is driving the global clinical trials market toward nearly USD 88.26 billion by 2032 at a 6.13% CAGR. ► Get a sample of the
Turbo Trainer Market to Reach USD 421.03 Million by 2032, Growing at a CAGR of 5.16% Driven
Turbo Trainer Market to Reach USD 421.03 Million by 2032, Growing at a CAGR of 5 …
Turbo Trainer Market size was valued at USD 281.52 Mn. in 2024 and the total Turbo Trainer revenue is expected to grow at 5.16% through 2025 to 2032, reaching nearly USD 421.03 Mn. Turbo Trainer Market Overview: The Turbo Trainer Market is witnessing significant growth as fitness enthusiasts increasingly adopt indoor cycling equipment for year-round training. Turbo trainers, which allow users to convert regular bicycles into stationary exercise machines, have become essential
Sodium Acetate Market to Reach USD 354.24 Million by 2032, Growing at a CAGR of 7% Driven
Sodium Acetate Market to Reach USD 354.24 Million by 2032, Growing at a CAGR of …
Sodium Acetate Market size was valued at USD 206.17 Million in 2024, and the total revenue is expected to grow at CAGR of 7 % from 2025 to 2032, reaching nearly USD 354.24 Million. Sodium Acetate Market Overview: The Sodium Acetate Market is experiencing steady growth due to its widespread applications across industries such as food and beverage, pharmaceuticals, textiles, and chemical manufacturing. Sodium acetate, a versatile salt of acetic acid, is
India Tire Market to Reach USD 27.6 Billion by 2033 at 7.6 % CAGR -
India Tire Market to Reach USD 27.6 Billion by 2033 at 7.6 % CAGR - "India Tire …
According to a new report by Maximize Market Research, the India tire market was valued at approximately USD 13.4 billion in 2024 and is expected to climb to USD 27.6 billion by 2033, representing a compound annual growth rate (CAGR) of about 7.6 %. The growth is underpinned by increasing automotive production, growing replacement demand, and rising adoption of radial tyres. ► Get a sample of the report:https://www.maximizemarketresearch.com/request-sample/21022/ ♦ Key Highlights Market size

All 5 Releases


More Releases for Biosimilar

Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period View sample report https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023 The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of